背景:HER2是乳腺癌治疗和预后的关键生物标志物。传统的评估方法,如免疫组织化学(IHC)和荧光原位杂交(FISH)是有效的,但昂贵且耗时。我们的模型将这些方法与光声成像结合在一起,以提高诊断准确性并提供更全面的临床见解。
方法:本研究共纳入301例乳腺肿瘤,分为HER2阳性(3+或2+有基因扩增)和HER2阴性(低于3+和2+无基因扩增)组。将样品以7:3的比例分成训练和验证集。统计分析涉及t检验,卡方检验,和等级检验。使用单变量和多变量逻辑回归确定预测因素,导致三个模型的创建:ModA(仅限临床因素),ModB(临床加超声因素),和ModC(临床,超声,和光声成像得出的氧饱和度(SO2))。
结果:ModA的曲线下面积(AUC)为0.756(95%CI:0.69-0.82),ModB增加到0.866(95%CI:0.82-0.91),和ModC表现出最高的性能,AUC为0.877(95%CI:0.83-0.92)。这些结果表明,综合模型结合临床,超声,和光声成像数据(ModC)在预测HER2表达方面表现最好。
结论:研究结果表明,整合临床,超声,和光声成像数据显着提高了预测HER2表达的准确性。对于个性化乳腺癌治疗,集成模型可以提供全面且可重复的决策支持工具。
BACKGROUND: HER2 is a key biomarker for breast cancer treatment and prognosis. Traditional assessment methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are effective but costly and time-consuming. Our model incorporates these methods alongside photoacoustic imaging to enhance diagnostic accuracy and provide more comprehensive clinical insights.
METHODS: A total of 301 breast tumors were included in this study, divided into HER2-positive (3+ or 2+ with gene amplification) and HER2-negative (below 3+ and 2+ without gene amplification) groups. Samples were split into training and validation sets in a 7:3 ratio. Statistical analyses involved t-tests, chi-square tests, and rank-sum tests. Predictive factors were identified using univariate and multivariate logistic regression, leading to the creation of three models: ModA (clinical factors only), ModB (clinical plus ultrasound factors), and ModC (clinical, ultrasound, and photoacoustic imaging-derived oxygen saturation (SO2)).
RESULTS: The area under the curve (AUC) for ModA was 0.756 (95 % CI: 0.69-0.82), ModB increased to 0.866 (95 % CI: 0.82-0.91), and ModC showed the highest performance with an AUC of 0.877 (95 % CI: 0.83-0.92). These results indicate that the comprehensive model combining clinical, ultrasound, and photoacoustic imaging data (ModC) performed best in predicting HER2 expression.
CONCLUSIONS: The findings suggest that integrating clinical, ultrasound, and photoacoustic imaging data significantly enhances the accuracy of predicting HER2 expression. For personalised breast cancer treatment, the integrated model could provide a comprehensive and reproducible decision support tool.